Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Common Equity (2016 - 2025)

CorMedix's Common Equity history spans 13 years, with the latest figure at $405.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 378.76% year-over-year to $405.3 million; the TTM value through Dec 2025 reached $405.3 million, up 378.76%, while the annual FY2025 figure was $405.3 million, 378.76% up from the prior year.
  • Common Equity for Q4 2025 was $405.3 million at CorMedix, up from $374.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $405.3 million in Q4 2025 and bottomed at $46.2 million in Q2 2024.
  • The 5-year median for Common Equity is $62.8 million (2021), against an average of $109.0 million.
  • The largest YoY upside for Common Equity was 221107.67% in 2021 against a maximum downside of 65.55% in 2021.
  • A 5-year view of Common Equity shows it stood at $62.8 million in 2021, then fell by 12.32% to $55.1 million in 2022, then skyrocketed by 51.11% to $83.2 million in 2023, then increased by 1.75% to $84.7 million in 2024, then surged by 378.76% to $405.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Common Equity are $405.3 million (Q4 2025), $374.1 million (Q3 2025), and $220.6 million (Q2 2025).